可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Lifton RP,Gharavi AG,Geller DS.Molecular mechanisms of human hypertension[J].Cell,2001,104(4):545-556.
[2]Young MJ,Rickard AJ.Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis[J].Mol Cell Endocrinol,2012,350(2):248-255.
[3]Hubmacher D,Apte SS.The biology of the extracellular matrix:novel insights[J].Curr Opin Rheumatol,2013,25(1):65-70.
[4]Kandasamy AD,Chow AK,Ali MA,et al.Matrix metalloproteinase-2 and myocardial oxidative stress injury:beyond the matrix[J].Cardiovasc Res,2010,85(3):413-423.
[5]Lacchini R,Jacob-Ferreira AL,Luizon MR,et al.Common matrix metalloproteinase 2 gene haplotypes May modulate left ventricular remodelling in hypertensive patients[J].J Hum Hypertens,2012,26(3):171-177.
[6]Caruso R,Caselli C,Boroni C,et al.Relationship between myocardial redox state and matrix metalloproteinase activity in patients on left ventricular assist device support[J].Circ J,2011,75(10):2387-2396.
[7]Wang X,Chow FL,Oka T,et al.Matrix metalloproteinase-7 and ADAM-12(a disintegrin and metalloproteinase-12)define a signaling axis in agonist-induced hypertension and cardiac hypertrophy[J].Circulation,2009,119(18):2480-2489.
[8]Wang X,Oka T,Chow FL,et al.Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis[J].Hypertension,2009,54(3):575-582.
[9]Baker AH,Edwards DR,Murphy G.Metalloproteinase inhibitors: biological actions and therapeutic opportunities[J].J Cell Sci,2002,115(Pt 19):3719-3727.
[10]Ahmed SH,Clark LL,Pennington WR,et al.Matrix metalloproteinases/tissue inhibitors of metalloproteinases:relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease[J].Circulation,2006,113(17):2089-2096.
[11]Lindsay MM,Maxwell P,Dunn FG.TIMP-1:a marker of left ventricular diastolic dysfunction and fibrosis in hypertension[J].Hypertension,2002,40(2):136-141.
[12]Siwik DA,Pagano PJ,Colucci WS.Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts[J].Am J Physiol Cell Physiol,2001,280(1):C53-C60.
[13]Brew K,Nagase H.The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity[J].Biochim Biophys Acta,2010,1803(1):55-71.
[14]Hitomi H,Kiyomoto H,Nishiyama A.Angiotensin II and oxidative stress[J].Curr Opin Cardiol,2007,22(4):311-315.
[15]Nishiyama A,Yoshizumi M,Rahman M,et al.Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats[J].Kidney Int,2004,65(3):972-981.
[16]Zhang GX,Kimura S,Nishiyama A,et al.ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction[J].Hypertension,2004,43(1):117-124.
[17]Galli A,Svegliati-Baroni G,Ceni E,et al.Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism[J].Hepatology,2005,41(5):1074-1084.
[18]Kelly PJ,Morrow JD,Ning M,et al.Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke)study[J].Stroke,2008,39(1):100-104.
[19]Spinale FG.Matrix metalloproteinases: regulation and dysregulation in the failing heart[J].Circ Res,2002,90(5):520-530.
[20]高修仁,彭龙云,麦炜颐,等.高血压大鼠心肌中MMP-2的蛋白表达及其RAS阻断后的变化[J].中山大学学报(医学科学版),2003,24(1):30-34.